AstraZeneca has paused an experimental vaccine for the coronavirus after the illness of a participant. The World Health Organization's (WHO) chief scientist said that is a “wake-up call” but should not discourage researchers.

Coronavirus vaccine: AstraZeneca pauses COVID-19 vaccine trial

The volunteer whose serious ailment halted clinical trials of a coronavirus vaccine candidate being developed by AstraZeneca and Oxford University

What do halted trials mean for the world?

Trials have stopped for the vaccine that was touted to be the frontrunner in the global race to combat coronavirus. In spite of being at the front of the race, trials for the vaccine being developed by AstraZeneca with Oxford University were put on hold.

The decision was taken after one of the participants showed serious and adverse reactions during the trials. When the trails were put on hold, they were being held in the US and UK. The participant suffering from the unexplained illness is expected to recover.

The story was first reported by health news website - Stat News

"Standard review process triggered a pause to vaccination to allow review of safety data,” Stat News&nbsp;quoted AstraZeneca spokesperson as saying.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-setback-for-oxfords-covid-19-vaccine-326394/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

In May, the US had ordered 300 million doses of the potential vaccine.&nbsp;Earlier this week, Australia announced that it had placed an order for 3.8 million doses with AstraZeneca.&nbsp;

The vaccine race has become highly political. Russian President Vladimir Putin had tested&nbsp;the Sputnik-V on his daughter. It&nbsp;is the vaccine for which there is no trial data available.&nbsp;Then there is China, where Sinovac is injecting its employees and their families with a potential vaccine.&nbsp;Again, it&nbsp;is a vaccine the world knows very little about.

Amidst all these covert trials, the transparency of one vaccine maker comes as a pleasant surprise.

There are still some companies that are not succumbing to political pressure to win the vaccine race. There are still some firms upholding the safety protocols even when political leaders advocate bypassing the critical stages of the trial.

Just yesterday, nine vaccine makers vowed not to cut corners on testing.&nbsp;AstraZeneca was one of the signatories

Others include Bio-N-Tech, Pfizer, Novovax, Sanofi, Glaxo-Smithkline, Johnson &amp; Johnson and Merck

Reacting to paused trials, Australia's Deputy Chief Medical Officer Nick Coatsworth said that the news was a testimony to safety and transparency.

"The fact that we're hearing about it and I'm talking about it, is testimony to the safety and the transparency. Both of which are such critical principles as we continue the race towards an effective COVID-19 vaccine," he said.

British Health Minister Matt Hancock echoed the sentiment.

"Well obviously I'd rather this went completely smoothly. However, we're absolutely clear that safety comes first with the vaccine so there's been a pause while they investigate an incident," he said.

These reactions are not surprising as Australia and UK both have stakes in a potential vaccine.&nbsp;The paused trial is a setback, no matter what British authorities tell you.

The world is in a dire need of a vaccine. The Wuhan virus has already taken 9,00,000 lives but the world needs a vaccine that can save lives, not take more. 
&nbsp;

Trials have stopped for the vaccine that was touted to be the frontrunner in the global race to combat coronavirus. In spite of being at the front of the race, trials for the vaccine being developed by AstraZeneca with Oxford University were put on hold.

Trials have stopped for the vaccine that was touted to be the frontrunner in the global race to combat coronavirus. In spite of being at the front of the race, trials for the vaccine being developed by AstraZeneca with Oxford University were put on hold. The decision was taken after one of the participants showed serious and adverse reactions during the trials. When the trails were put on hold, they were being held in the US and UK. The participant suffering from the unexplained illness is expected to recover. The story was first reported by health news website - Stat News "Standard review process triggered a pause to vaccination to allow review of safety data,” Stat News quoted AstraZeneca spokesperson as saying. × In May, the US had ordered 300 million doses of the potential vaccine. Earlier this week, Australia announced that it had placed an order for 3.8 million doses with AstraZeneca. The vaccine race has become highly political. Russian President Vladimir Putin had tested the Sputnik-V on his daughter. It is the vaccine for which there is no trial data available. Then there is China, where Sinovac is injecting its employees and their families with a potential vaccine. Again, it is a vaccine the world knows very little about. Amidst all these covert trials, the transparency of one vaccine maker comes as a pleasant surprise. There are still some companies that are not succumbing to political pressure to win the vaccine race. There are still some firms upholding the safety protocols even when political leaders advocate bypassing the critical stages of the trial. Just yesterday, nine vaccine makers vowed not to cut corners on testing. AstraZeneca was one of the signatories Others include Bio-N-Tech, Pfizer, Novovax, Sanofi, Glaxo-Smithkline, Johnson & Johnson and Merck Reacting to paused trials, Australia's Deputy Chief Medical Officer Nick Coatsworth said that the news was a testimony to safety and transparency. "The fact that we're hearing about it and I'm talking about it, is testimony to the safety and the transparency. Both of which are such critical principles as we continue the race towards an effective COVID-19 vaccine," he said. British Health Minister Matt Hancock echoed the sentiment. "Well obviously I'd rather this went completely smoothly. However, we're absolutely clear that safety comes first with the vaccine so there's been a pause while they investigate an incident," he said. These reactions are not surprising as Australia and UK both have stakes in a potential vaccine. The paused trial is a setback, no matter what British authorities tell you. The world is in a dire need of a vaccine. The Wuhan virus has already taken 9,00,000 lives but the world needs a vaccine that can save lives, not take more.

Trials of Oxford University's COVID-19 vaccine 'paused', what now?

The development of the promising Oxford vaccine has been put on hold by AstraZeneca. This is after one participant suffered what may have been a serious adverse reaction. Is this a major setback?

Gravitas: Setback for Oxford's COVID-19 vaccine

After it "paused" its clinical trial over the vaccine this week, AstraZeneca's CEO Pascal Soriot said today that a vaccine was still possible by the "end of this year, early next year".

After it "paused" its clinical trial over the vaccine this week, AstraZeneca's CEO Pascal Soriot said today that a vaccine was still possible by the "end of this year, early next year". Watch: The company stopped its late-stage trials after a participant in Britain fell ill. The volunteer reportedly had a rare spinal inflammatory disorder called transverse myelitis, but a final diagnosis is pending with more tests underway. Also Read: AstraZeneca 'voluntarily pauses' clinical trials for Oxford's COVID-19 vaccine US National Institutes of Health Director Francis Collins told a Senate committee hearing that "work was underway to see if anybody else who received that vaccination or any other might have had a similar finding of a spinal cord problem." Pascal Soriot said the company should know before the end of the year whether its experimental vaccine protects people against coronavirus. "We could still have a vaccine by the end of this year, early next year," he added. Also Read: Trials of Oxford University's COVID-19 vaccine 'paused', what now? Soriot said pausing trials was not a new phenomena. "It's very common, actually, and many experts will tell you this," Soriot said, adding: "The difference with other vaccine trials is, the whole world is not watching them, of course. They stop, they study, and they restart." AstraZeneca's CEO informed that it has capacity for 3 billion doses at sites around the world to prevent governments from restricting distribution. "AstraZeneca would supply vaccines to countries at the same time to ensure a fair and equitable distribution," Soriot said.

Could still have a vaccine by the end of the year, early next year: AstraZeneca CEO

Pharmaceuticals giant AstraZeneca on Tuesday said that it had to &nbsp;"voluntarily paused" a randomized clinical trial of its coronavirus vaccine. The company called it a routine action after a volunteer developed an unexplained illness.

Also read:&nbsp;<a href="https://www.wionews.com/world/china-handled-covid-19-openly-and-transparently-xi-jinping-325898" hreflang="en">China handled COVID-19 openly and transparently: Xi Jinping</a>

AstraZeneca is developing the drug alongside the University of Oxford and is considered the frontrunner in the global race for a vaccine against coronavirus.&nbsp;

"As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee," a spokesperson said.

Also read:&nbsp;<a href="https://www.wionews.com/world/russia-releases-first-batch-of-covid-19-vaccine-sputnik-v-into-public-325883" hreflang="en">Russia releases first batch of Covid-19 vaccine Sputnik V into public</a>

"This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials."

The company spokesperson also added that in large trials, illnesses will sometimes happen by chance but must be reviewed independently.

"We are working to expedite the review of the single event to minimise any potential impact on the trial timeline," the spokesperson said.

The nature and severity of illness or where the patient was not clear immediately.&nbsp;

Pauses during clinical trials are common. But, this is thought to be the first time it has happened for a Covid-19 vaccine trial.

AstraZeneca is one of nine companies currently in late-stage Phase 3 trials for their vaccine candidates.

Pharmaceuticals giant AstraZeneca on Tuesday said that it had to "voluntarily paused" a randomized clinical trial of its coronavirus vaccine. The company called it a routine action after a volunteer developed an unexplained illness.

Pharmaceuticals giant AstraZeneca on Tuesday said that it had to "voluntarily paused" a randomized clinical trial of its coronavirus vaccine. The company called it a routine action after a volunteer developed an unexplained illness. Also read: China handled COVID-19 openly and transparently: Xi Jinping AstraZeneca is developing the drug alongside the University of Oxford and is considered the frontrunner in the global race for a vaccine against coronavirus. "As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee," a spokesperson said. Also read: Russia releases first batch of Covid-19 vaccine Sputnik V into public "This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials." The company spokesperson also added that in large trials, illnesses will sometimes happen by chance but must be reviewed independently. "We are working to expedite the review of the single event to minimise any potential impact on the trial timeline," the spokesperson said. The nature and severity of illness or where the patient was not clear immediately. Pauses during clinical trials are common. But, this is thought to be the first time it has happened for a Covid-19 vaccine trial. AstraZeneca is one of nine companies currently in late-stage Phase 3 trials for their vaccine candidates.

AstraZeneca 'voluntarily pauses' clinical trials for Oxford's COVID-19 vaccine after unexplained illness

AstraZeneca Covid-19 vaccine study is on a temporary hold after a participant falls ill. AstraZeneca didn't reveal any information about the possible side effect expect to call it 'a potentially unexplained illness'.

WION Fineprint: Oxford-Astrazeneca pause major trial for second time

AstraZeneca COVID-19 vaccine study paused after a participant falls ill in UK

After Russia, these COVID-19 vaccines set to unveil soon!

AstraZeneca on Tuesday said that it had begun a clinical trial of a drug designed to both prevent infection and treat people with COVID-19, with the first volunteers receiving doses.

AstraZeneca on Tuesday said that it had begun a clinical trial of a drug designed to both prevent infection and treat people with COVID-19, with the first volunteers receiving doses. Also read: Second wave of Covid-19? Re-infections in Belgium and the Netherlands make experts wary According to the pharma giant, the drug, known as AZD7442, is a combination of two antibodies and is being tested on 48 healthy people aged between 18 and 55. "This trial is an important milestone in the development of our monoclonal antibody combination to prevent or treat COVID-19," said Mene Pangalos, executive vice-president of biopharmaceuticals research and development at AstraZeneca. Also read: Pandemic pace slows worldwide except for Southeast Asia, Eastern Mediterranean: WHO The pharmaceuticals company said that such trials would help evaluate the safety of the drug and be used both to prevent the disease and to stop it from progressing in patients already infected. Results from the trial are expected by the end of this year. This latest trial involving AstraZeneca comes in addition to its partnership with the University of Oxford on the development of a separate coronavirus vaccine, which is said to have produced promising results. News of the latest trial helped shares in AstraZeneca to rise in early trading on Tuesday. (Inputs from agencies)

AstraZeneca conducts clinical trials of COVID-19 drug

AstraZeneca Plc on Thursday signed a deal with a China-based company for producing its potential drug to treat novel coronavirus in mainland China.&nbsp;

Shenzhen Kangtai Biological Products becomes the first Chinese company to enter into a deal with AstraZeneca.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/oxford-astrazeneca-coronavirus-vaccine-trial-safe-produced-immune-response-data-reveals-314716">Oxford-AstraZeneca coronavirus vaccine trial: Safe &amp; produced immune response, data reveals</a> &nbsp;

AZD1222, that is jointly developed by AstraZeneca and Oxford Univesity, is one of the frontrunners in COVID-19 vaccine race.

Also read |&nbsp;<a href="https://www.wionews.com/world/brazil-signs-agreement-to-produce-astrazenecas-experimental-covid-19-vaccine-309047">Brazil signs agreement to produce AstraZeneca's experimental COVID-19 vaccine</a>

The agreement says that Shenzhen Kangtai will annually produce at least 100 million doses of AZD1222 and must be able to stretch it to 200 million doses by the end of 2021, AstraZeneca said on Thursday.&nbsp;

It also said the two pharma giants will seek the possibility of cooperation on the vaccine candidate in other markets.&nbsp;

Earlier, AstraZeneca has signed production deals with countries like the US, India, Britain, South Korea, which overall leads to the manufacturing of over two billion doses.&nbsp;

Chinese organisations have earlier tied up with other Western pharma firms such as Germany's BioNTech and US's Inovio Pharma for producing coronavirus vaccine.&nbsp;

Shenzhen Kangtai is one of China's leading vaccine makers and its shares have surged nearly 90 per cent to about $20 billion in the last one month, with its stocks witnessing a record-high on Tuesday. 
&nbsp;

AstraZeneca Plc on Thursday signed a deal with a China-based company for producing its potential drug to treat novel coronavirus in mainland China. Shenzhen Kangtai Biological Products becomes the first Chinese company to enter into a deal with AstraZeneca.

AstraZeneca Plc on Thursday signed a deal with a China-based company for producing its potential drug to treat novel coronavirus in mainland China. Shenzhen Kangtai Biological Products becomes the first Chinese company to enter into a deal with AstraZeneca. Also read | Oxford-AstraZeneca coronavirus vaccine trial: Safe & produced immune response, data reveals AZD1222, that is jointly developed by AstraZeneca and Oxford Univesity, is one of the frontrunners in COVID-19 vaccine race. Also read | Brazil signs agreement to produce AstraZeneca's experimental COVID-19 vaccine The agreement says that Shenzhen Kangtai will annually produce at least 100 million doses of AZD1222 and must be able to stretch it to 200 million doses by the end of 2021, AstraZeneca said on Thursday. It also said the two pharma giants will seek the possibility of cooperation on the vaccine candidate in other markets. Earlier, AstraZeneca has signed production deals with countries like the US, India, Britain, South Korea, which overall leads to the manufacturing of over two billion doses. Chinese organisations have earlier tied up with other Western pharma firms such as Germany's BioNTech and US's Inovio Pharma for producing coronavirus vaccine. Shenzhen Kangtai is one of China's leading vaccine makers and its shares have surged nearly 90 per cent to about $20 billion in the last one month, with its stocks witnessing a record-high on Tuesday.

AstraZeneca signs first deal with Chinese firm to produce COVID-19 vaccine

Brazil announced on Saturday that it had signed a $127 million agreement to start producing locally an experimental vaccine developed by AstraZeneca that has shown promise to fight the COVID-19 pandemic.

The AstraZeneca vaccine is considered the world’s leading candidate and most advanced in terms of development to obtain licensure and become an official vaccine against the disease, according to the World Health Organisation.

The British drugmaker is already carrying out large-scale, mid-stage human trials of the vaccine, which was developed by researchers at Oxford University.

Elcio Franco, Brazil’s No. 2 public health official, said in a press conference that the country will initially produce some 30 million doses of the vaccine, half by December and half by January of next year.

Franco said Brazil is paying for the vaccine but is aware of the risk, in case the vaccine does not pass all necessary licensure requirements or another vaccine obtains approval faster.

The vaccine will be produced by Brazil’s Fundação Osvaldo Cruz, also known as Fiocruz, the country’s leading public health organisation, Franco said.

Brazil is the world’s second most affected country by the coronavirus pandemic, with more than 1.2 million confirmed cases as of Friday and more than 55,000 deaths.

Right-wing President Jair Bolsonaro has been widely criticized for this response to the pandemic. He has dismissed the severity of the disease and has shown indifference to the rising death toll while also pushing treatment using an unproven anti-malaria drug.

Brazil announced on Saturday that it had signed a $127 million agreement to start producing locally an experimental vaccine developed by AstraZeneca that has shown promise to fight the COVID-19 pandemic.

Brazil announced on Saturday that it had signed a $127 million agreement to start producing locally an experimental vaccine developed by AstraZeneca that has shown promise to fight the COVID-19 pandemic. The AstraZeneca vaccine is considered the world’s leading candidate and most advanced in terms of development to obtain licensure and become an official vaccine against the disease, according to the World Health Organisation. The British drugmaker is already carrying out large-scale, mid-stage human trials of the vaccine, which was developed by researchers at Oxford University. Elcio Franco, Brazil’s No. 2 public health official, said in a press conference that the country will initially produce some 30 million doses of the vaccine, half by December and half by January of next year. Franco said Brazil is paying for the vaccine but is aware of the risk, in case the vaccine does not pass all necessary licensure requirements or another vaccine obtains approval faster. The vaccine will be produced by Brazil’s Fundação Osvaldo Cruz, also known as Fiocruz, the country’s leading public health organisation, Franco said. Brazil is the world’s second most affected country by the coronavirus pandemic, with more than 1.2 million confirmed cases as of Friday and more than 55,000 deaths. Right-wing President Jair Bolsonaro has been widely criticized for this response to the pandemic. He has dismissed the severity of the disease and has shown indifference to the rising death toll while also pushing treatment using an unproven anti-malaria drug.

Brazil signs agreement to produce AstraZeneca's experimental COVID-19 vaccine

AstraZeneca is one of the front runners in the race to protect against coronavirus for about a year, the company's chief executive told a Belgian radio station on Tuesday.

AstraZeneca is one of the front runners in the race to protect against coronavirus for about a year, the company's chief executive told a Belgian radio station on Tuesday. Also read: COVID-19: Beijing reports another 27 cases amid second wave fears The vaccines developed by the University of Oxford have begun with human trials with a phase I trial in Britain due to end soon and a phase III trial already begun, Pascal Soriot told broadcaster Bel RTL. "We think that it will protect for about a year," Soriot said. The British drugmaker has signed contracts with France, Germany, Italy and the Netherlands to supply the EU with up to 400 million doses of the vaccine. Britain and the United States are also a part of the deal. "If all goes well, we will have the results of the clinical trials in August/September. We are manufacturing in parallel. We will be ready to deliver from October if all goes well," Soriot said. (Inputs from Reuters)

Vaccine developed by AstraZeneca most likely to protect for a year: CEO

AstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc about a potential merger.

Any deal would bring together two of the companies leading the drug industry's efforts to fight the coronavirus pandemic, according to Bloomberg News.

AstraZeneca contacted Gilead last month and it did not provide the terms of any transaction, the report added.

Gilead, AstraZeneca and several other drugmakers, including Eli Lilly and Co, Pfizer Inc and Merck &amp; Co Inc, are racing to develop vaccines or treatments for COVID-19, the respiratory illness caused by the novel coronavirus.

More than 6.90 million people have been reported infected with the coronavirus globally and 399,025 have died.

Gilead is not interested in selling to or merging with another big pharmaceutical company, and prefers instead to focus its deal strategy on partnerships and smaller acquisitions, the report said.

AstraZeneca said on June 4 it had doubled manufacturing capacity for its potential coronavirus vaccine to 2 billion doses in two deals involving Microsoft billionaire Bill Gates that guarantee early supply to lower income countries. It is unclear if a vaccine will work, but&nbsp; 
AstraZeneca's partnership with Oxford University to develop one is among a handful of initiatives US President Donald Trump's COVID task force has backed. Gilead has also been at the forefront. Its Remdesivir antiviral is the first drug to lead to improvement in COVID-19 patients in formal clinical trials.

(with inputs from Reuters)

AstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc about a potential merger. Any deal would bring together two of the companies leading the drug industry's efforts to fight the coronavirus pandemic, according to Bloomberg News.

AstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc about a potential merger. Any deal would bring together two of the companies leading the drug industry's efforts to fight the coronavirus pandemic, according to Bloomberg News. AstraZeneca contacted Gilead last month and it did not provide the terms of any transaction, the report added. Gilead, AstraZeneca and several other drugmakers, including Eli Lilly and Co, Pfizer Inc and Merck & Co Inc, are racing to develop vaccines or treatments for COVID-19, the respiratory illness caused by the novel coronavirus. More than 6.90 million people have been reported infected with the coronavirus globally and 399,025 have died. Gilead is not interested in selling to or merging with another big pharmaceutical company, and prefers instead to focus its deal strategy on partnerships and smaller acquisitions, the report said. AstraZeneca said on June 4 it had doubled manufacturing capacity for its potential coronavirus vaccine to 2 billion doses in two deals involving Microsoft billionaire Bill Gates that guarantee early supply to lower income countries. It is unclear if a vaccine will work, but AstraZeneca's partnership with Oxford University to develop one is among a handful of initiatives US President Donald Trump's COVID task force has backed. Gilead has also been at the forefront. Its Remdesivir antiviral is the first drug to lead to improvement in COVID-19 patients in formal clinical trials. (with inputs from Reuters)

AstraZeneca and Gilead may head for a merger, says report

AstraZeneca's cancer drug Calquence has shown initial signs of helping hospitalised COVID-19 patients get through the worst of the disease, as researchers scramble to repurpose existing treatments to help fight the deadly infection.

Results from the preliminary research involving 19 patients, which was backed by the United States National Institutes of Health, encouraged the British drugmaker to explore the drug's new use in a wider clinical trial announced in April.

Also read: <a href="https://www.wionews.com/world/us-secures-300-million-doses-of-potential-astrazeneca-coronavirus-vaccine-300182">US secures 300 million doses of potential AstraZeneca coronavirus vaccine</a>

Eleven patients had been on oxygen when they started the 10-14 day Calquence course and eight of them could afterwards be discharged, breathing independently, according to results in a paper co-authored by Astra's head of oncology research, Jose Baselga.

Eight patients were on mechanical ventilation when they were put on Calquence, and four of them could be discharged, though one died of pulmonary embolism.

"These patients were in a very unstable situation, they would have had a dire prognosis ... Within one to three days the majority of these patients got better in terms of ventilation and oxygen needs," Astra's Baselga told Reuters.

Severe cases of COVID-19 are believed to be triggered by an over-reaction of the immune system known as cytokine storm and initial research has brought Calquence, and other drugs that suppress certain elements of the immune system, into play.

Autoimmune disease drugs that are being tested for their ability to quell the cytokine storm include Regeneron&nbsp; and Sanofi's Kevzara, Roche's&nbsp;Actemra as well as Morphosys&nbsp;and GlaxoSmithKline's&nbsp;otilimab.

In its approved use, Calquence competes with AbbVie and Johnson &amp; Johnson’s established treatment Imbruvica as a treatment for chronic lymphocytic leukaemia, a common type of adult leukaemia.

AstraZeneca's cancer drug Calquence has shown initial signs of helping hospitalised COVID-19 patients get through the worst of the disease, as researchers scramble to repurpose existing treatments to help fight the deadly infection.

AstraZeneca's cancer drug Calquence has shown initial signs of helping hospitalised COVID-19 patients get through the worst of the disease, as researchers scramble to repurpose existing treatments to help fight the deadly infection. Results from the preliminary research involving 19 patients, which was backed by the United States National Institutes of Health, encouraged the British drugmaker to explore the drug's new use in a wider clinical trial announced in April. Also read: US secures 300 million doses of potential AstraZeneca coronavirus vaccine Eleven patients had been on oxygen when they started the 10-14 day Calquence course and eight of them could afterwards be discharged, breathing independently, according to results in a paper co-authored by Astra's head of oncology research, Jose Baselga. Eight patients were on mechanical ventilation when they were put on Calquence, and four of them could be discharged, though one died of pulmonary embolism. "These patients were in a very unstable situation, they would have had a dire prognosis ... Within one to three days the majority of these patients got better in terms of ventilation and oxygen needs," Astra's Baselga told Reuters. Severe cases of COVID-19 are believed to be triggered by an over-reaction of the immune system known as cytokine storm and initial research has brought Calquence, and other drugs that suppress certain elements of the immune system, into play. Autoimmune disease drugs that are being tested for their ability to quell the cytokine storm include Regeneron and Sanofi's Kevzara, Roche's Actemra as well as Morphosys and GlaxoSmithKline's otilimab. In its approved use, Calquence competes with AbbVie and Johnson & Johnson’s established treatment Imbruvica as a treatment for chronic lymphocytic leukaemia, a common type of adult leukaemia.

AstraZeneca blood cancer drug shows signs of helping COVID-19 patients

Britain's pharmaceutical company AstraZeneca will be able to deliver nearly 2 billion doses of the coronavirus vaccine if they succeed in making one. These figures are double the previous claims because of deals with the Serum Institute of India and two Bill Gates-backed global health organisations.

Also read:&nbsp;<a href="https://www.wionews.com/world/covid-19-vaccine-for-global-public-good-says-un-chief-antonio-guterres-at-virtual-global-vaccine-summit-in-london-303340" hreflang="en">COVID-19 vaccine for global public good, says UN chief Antonio Guterres at virtual Global Vaccine Summit in London</a>

Serum Institute of India is the world's largest manufacturers of vaccines in terms of volume.&nbsp;

AstraZeneca has already promised 400 million doses to the United States and Britain and on Thursday they agreed to terms with the Indian company to supply one billion doses to low and middle-income countries.

The British-based pharmaceutical company's tie-up with Oxford University has gathered attention as one of the leading candidates to make a coronavirus vaccine. The US government has funded &nbsp;$1 billion for its work.&nbsp;

The company will produce an additional 300 million doses after a $750 million agreement was signed with the Coalition for Epidemic Preparedness Innovations and GAVI vaccines alliance, both founded by Microsoft-founder Gates and his wife.&nbsp;

Britain's pharmaceutical company AstraZeneca will be able to deliver nearly 2 billion doses of the coronavirus vaccine if they succeed in making one. These figures are double the previous claims because of deals with the Serum Institute of India and two Bill Gates-backed global health organisations.

Britain's pharmaceutical company AstraZeneca will be able to deliver nearly 2 billion doses of the coronavirus vaccine if they succeed in making one. These figures are double the previous claims because of deals with the Serum Institute of India and two Bill Gates-backed global health organisations. Also read: COVID-19 vaccine for global public good, says UN chief Antonio Guterres at virtual Global Vaccine Summit in London Serum Institute of India is the world's largest manufacturers of vaccines in terms of volume. AstraZeneca has already promised 400 million doses to the United States and Britain and on Thursday they agreed to terms with the Indian company to supply one billion doses to low and middle-income countries. The British-based pharmaceutical company's tie-up with Oxford University has gathered attention as one of the leading candidates to make a coronavirus vaccine. The US government has funded $1 billion for its work. The company will produce an additional 300 million doses after a $750 million agreement was signed with the Coalition for Epidemic Preparedness Innovations and GAVI vaccines alliance, both founded by Microsoft-founder Gates and his wife.

Britain's AstraZeneca ties up with two companies to provide two billion doses

astrazeneca

Astrazeneca, News on Astrazeneca, stories on Astrazeneca, articles on Astrazeneca, Astrazeneca stories at Wion, Astrazeneca news, Astrazeneca latest news